Danazol in the treatment of Precocious Puberty

Treatment of Peripheral Precocious Puberty.

There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate ...

Cyproterone acetate in treatment of precocious puberty.

Twenty-nine children (23 girls, 6 boys) with precocious puberty were treated with cyproterone acetate for various periods of time ranging from 6 months to 3 years 4 months. They received an oral dose ranging from 70-150 mg/m2 per day, or an intramuscular depot injection once a fortnight or once a month at a dose ranging from 107-230 mg/m2. Both forms of therapy were found to suppress the signs ...

Precocious Puberty

From the Department of Pediatric Endocrinology and Diabetology, INSERM Unité 690, and Centre de Référence des Maladies Endocriniennes de la Croissance, Robert Debré Hospital and University of Paris 7 — Denis Diderot, Paris (J.-C.C., J.L.). Address reprint requests to Dr. Carel at Endocrinologie Diabétologie Pédiatrique and INSERM U690, Hôpital Robert Debré, 48, Blvd. Sérurier, 75935 Paris CEDEX...

Precocious Puberty.

Precocious puberty (PP) has traditionally been defined as pubertal changes occurring before age 8 years in girls and 9 years in boys. A secular trend toward earlier puberty has now been confirmed by recent studies in both the United States and Europe. Factors associated with earlier puberty include obesity, endocrine-disrupting chemicals (EDC), and intrauterine growth restriction. In 1997, a st...

Precocious Puberty